PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada.\', \'University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada.\', \'BC Centre for Disease Control, Data and Analytics Services, Vancouver, British Columbia, Canada.\', \'BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada.\', \'University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada.\', \'Office of the Provincial Health Officer, Ministry of Health, Victoria, British Columbia, Canada.\', \'BC Children\'s Hospital Research Institute, Vaccine Evaluation Center, Vancouver, British Columbia, Canada.\', \'University of British Columbia, Department of Pediatrics, Vancouver, British Columbia, Canada.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1093/cid/ciab616
?:hasPublicationType
?:journal
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
is ?:pmid of
?:pmid
?:pmid
  • 34244723
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all